Alphyn Biologics is improving therapy for diseases with its platform AB-101 patent-pending biomaterial that has over 40 bio-active compounds. AB-101’s over 40 bioactive allow it to both treat and cure many different diseases, and, provide multiple ways to attack each disease, leading the way in a new class of drugs called Multi-target Therapeutics.
Alphyn’s first product targets Methicillin-resistant Staphylococcus aureus (MRSA) skin infections. MRSA is difficult to treat because it is resistant to the commonly used antibiotics. The CDC considers MRSA, sometimes called a “superbug”, one of the biggest threats to human health.1 The current topical drugs of choice for treating MRSA are reported ineffective 30 – 80% of the time and are declining in efficacy as MRSA resistance grows.2, 3 Alphyn’s Multi-target Therapeutic for MRSA drug resistant infections is expected to be highly efficacious and fight development of resistance.